South Korea · Delayed Price · Currency is KRW GL Pharm Tech Statistics
Total Valuation
GL Pharm Tech has a market cap or net worth of KRW 84.06 billion. The enterprise value is 99.76 billion.
| Market Cap | 84.06B |
| Enterprise Value | 99.76B |
Important Dates
The next estimated earnings date is Wednesday, April 1, 2026.
| Earnings Date | Apr 1, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GL Pharm Tech has 77.55 million shares outstanding. The number of shares has increased by 8.41% in one year.
| Current Share Class | 77.55M |
| Shares Outstanding | 77.55M |
| Shares Change (YoY) | +8.41% |
| Shares Change (QoQ) | +4.80% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 54.46M |
Valuation Ratios
The trailing PE ratio is 6,730.99.
| PE Ratio | 6,730.99 |
| Forward PE | n/a |
| PS Ratio | 2.38 |
| PB Ratio | 4.22 |
| P/TBV Ratio | 4.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 64.38, with an EV/FCF ratio of -23.06.
| EV / Earnings | 7,987.84 |
| EV / Sales | 2.83 |
| EV / EBITDA | 64.38 |
| EV / EBIT | 182.19 |
| EV / FCF | -23.06 |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 0.94.
| Current Ratio | 1.01 |
| Quick Ratio | 0.48 |
| Debt / Equity | 0.94 |
| Debt / EBITDA | 14.75 |
| Debt / FCF | -4.33 |
| Interest Coverage | 0.46 |
Financial Efficiency
Return on equity (ROE) is 0.06% and return on invested capital (ROIC) is 1.75%.
| Return on Equity (ROE) | 0.06% |
| Return on Assets (ROA) | 0.37% |
| Return on Invested Capital (ROIC) | 1.75% |
| Return on Capital Employed (ROCE) | 0.98% |
| Weighted Average Cost of Capital (WACC) | 6.27% |
| Revenue Per Employee | 1.07B |
| Profits Per Employee | 378,454 |
| Employee Count | 33 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 2.15 |
Taxes
In the past 12 months, GL Pharm Tech has paid 63.51 million in taxes.
| Income Tax | 63.51M |
| Effective Tax Rate | 83.57% |
Stock Price Statistics
The stock price has increased by +10.39% in the last 52 weeks. The beta is 0.60, so GL Pharm Tech's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | +10.39% |
| 50-Day Moving Average | 1,078.80 |
| 200-Day Moving Average | 1,160.68 |
| Relative Strength Index (RSI) | 50.16 |
| Average Volume (20 Days) | 248,313 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GL Pharm Tech had revenue of KRW 35.27 billion and earned 12.49 million in profits.
| Revenue | 35.27B |
| Gross Profit | 14.28B |
| Operating Income | 268.48M |
| Pretax Income | 76.00M |
| Net Income | 12.49M |
| EBITDA | 1.27B |
| EBIT | 268.48M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 3.04 billion in cash and 18.73 billion in debt, with a net cash position of -15.70 billion or -202.41 per share.
| Cash & Cash Equivalents | 3.04B |
| Total Debt | 18.73B |
| Net Cash | -15.70B |
| Net Cash Per Share | -202.41 |
| Equity (Book Value) | 19.92B |
| Book Value Per Share | n/a |
| Working Capital | 222.22M |
Cash Flow
In the last 12 months, operating cash flow was -1.12 billion and capital expenditures -3.20 billion, giving a free cash flow of -4.33 billion.
| Operating Cash Flow | -1.12B |
| Capital Expenditures | -3.20B |
| Depreciation & Amortization | 1.13B |
| Net Borrowing | 2.56B |
| Free Cash Flow | -4.33B |
| FCF Per Share | -55.80 |
Margins
Gross margin is 40.49%, with operating and profit margins of 0.76% and 0.04%.
| Gross Margin | 40.49% |
| Operating Margin | 0.76% |
| Pretax Margin | 0.22% |
| Profit Margin | 0.04% |
| EBITDA Margin | 3.60% |
| EBIT Margin | 0.76% |
| FCF Margin | n/a |
Dividends & Yields
GL Pharm Tech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.41% |
| Shareholder Yield | -8.41% |
| Earnings Yield | 0.01% |
| FCF Yield | -5.15% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GL Pharm Tech has an Altman Z-Score of 1.94 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.94 |
| Piotroski F-Score | 4 |